Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of the effect of transversus abdominis plane block or conventional analgesia on pain scores, patient satisfaction and incidence of chronic pelvic pain after total abdominal hysterectomy: a randomised double-blind controlled trial.

Trial Profile

Comparison of the effect of transversus abdominis plane block or conventional analgesia on pain scores, patient satisfaction and incidence of chronic pelvic pain after total abdominal hysterectomy: a randomised double-blind controlled trial.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levobupivacaine (Primary) ; Morphine; Paracetamol
  • Indications Pelvic pain; Postoperative pain
  • Focus Therapeutic Use

Most Recent Events

  • 16 Nov 2011 Actual initiation date changed from Nov 2008 to Aug 2008 as reported by European Clinical Trials Database record.
  • 16 Nov 2011 Trial phase changed from II to IV as reported by European Clinical Trials Database record.
  • 16 Nov 2011 New source identified and integrated (European Clinical Trials Database: EudraCT2008-003168-20)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top